In space, astronauts are exposed to a large doses of ionizing radiation which can cause various health problems. The drug delivery of antioxidants and anti-inflammatory substances is a promising countermeasure for the harmful cellular effects of radiation exposure. Curcumin is a polyphenol derived from the rhizome of the turmeric plant that has strong antioxidant capabilities. The therapeutic potential of this radical scavenging drug is limited by poor uptake in the body due to its insolubility in water, rapid metabolism by the intestinal mucosa and liver, and quick excretion. Drug delivery vehicles can be used to enhance the bioavailability of curcumin. Albumin, a biodegradable and non-immunogenic plasma protein, can be utilized as a drug delivery vehicle. Curcumin binds to albumin's hydrophobic pockets, which increases its solubility and decreases its rate of degradation in physiological conditions. Curcumin was solubilized with 0.5% (w/v) fatty acid free human serum albumin (FAF HSA) and spray dried to form a dry powder of particles. To produce particles with a smooth and spherical morphology, 0.05% (v/v) Tween® 20 was included in the solution. Curcumin release from these particles followed a first-order release profile (Ct/Cinf = 1 -e kt , t = time in min) with k = 0.065 ± 0.003.
x LIST OF FIGURES FIGURE 1 -Schematic drawing of HSA (Sugio et al., 1999) A. Background Astronauts are exposed to increased levels of ionizing radiation while in space. With this increased exposure comes a multitude of health risks including the potential to develop cancer (Durante and Cucinotta, 2008) . (Cucinotta and Durante, 2006; Rask, 2008) . As can be seen, protection from radiation becomes increasingly important as missions become longer and take humans deeper into space. The development of effective countermeasures is critical to advancing human deep space exploration.
There are three main methods for limiting exposure to ionizing radiation. The first is to move further away from the radiation source. This is not possible in space because space radiation is omnidirectional. The second way to reduce exposure is to decrease the exposure time, but manned missions will only get longer as humans travel farther away from Earth to other planets, asteroids, and beyond. The last method for limiting exposure to ionizing radiation is shielding. Though plausible, the additional mass from the shielding would likely exceed current launch capabilities. Attempts are made to minimize harm via strategic launch schedules and astronaut selection of individuals with lower susceptibility to the effects of radiation exposure (Cucinotta and Durante, 2009 ). indirect production of free radicals from water molecules (Cucinotta and Durante, 2009 ). Cellular damage is followed by an inflammatory response. Most chronic diseases are the result of chronic dysregulation of the inflammatory response (Aggarwal, 2007) . Since exposure to radiation during space travel is currently unavoidable, countermeasures that work to oppose these harmful effects become increasingly important. The development of delivery systems for antioxidant and anti-inflammatory drugs is one such countermeasure.
Curcumin (diferuloylmethane) is a highly active polyphenol component of Curcuma longa (commonly known as turmeric), an herb frequently used as a food additive and preservative. It comes from the dried rhizome of the turmeric plant, and demonstrates chemopreventative activities as a result of its antioxidant and anti-inflammatory properties. Curcumin is a good scavenger of free radicals. Additionally, it can inhibit expression or suppress production of pro-inflammatory markers (Anand et al., 2007) . It does not show toxicity and has been safely tested at dosage levels of 8 g/day in humans (Cheng et al., 2001) .
The therapeutic potential of curcumin is limited by its poor bioavailability. These bioavailability limitations can be attributed to curcumin's virtual insolubility in biological fluids and rapid degradation at physiologic pH (Hatcher et al., 2008; Sharma et al., 2005) .
The oral intake of 3.6 g of curcumin, has been shown to peak serum curcumin levels at 11.1 nmol/L after one hour of dosing (Sharma et al., 2004) . At physiologic pH, curcumin degradation into feruloylmethane and vanillin occurs within 30 minutes (Lin et al., 2000) .
Intravenous administration of curcumin would be a preferred route of delivery because it would allow curcumin to bypass rapid degradation by the intestinal mucosa (Anand et al., 2007) . For this administration to work, curcumin's solubility in biological fluids would need to be addressed, and solvent-based delivery vehicles are one approach for doing so (Fu et al., 2009) . Nanoparticles are often used in solvent-based delivery vehicles because they allow for controlled drug release to happen over time and with a predictable profile. (Atala and Lanza, 2002; Michnik et al., 2006) . For example, nanoparticle albumin-bound paclitaxil was approved by the Food and Drug Administration in 2006 to treat metastatic breast cancer (Fu et al., 2009) . The molecular structure of albumin (FIGURE 1) consists of six subdomains and six sites for binding fatty acids (Pulla Reddy et al., 1999; Sugio et al., 1999) . These sites can serve as pockets that bind hydrophobic drugs such as curcumin, allowing them to become solubilized and protecting them from degradation, improving their bioavailability. Albumin has been shown to bind curcumin with 2:1 stoichiometry (Pulla Reddy et al., 1999) . FIGURE 1 -Schematic drawing of HSA (Sugio et al., 1999) Techniques such as emulsification, desolvation, and thermal gelation have all been used to produce albumin nanoparticles (Elzoghby et al., 2012) . Spray drying, another technique, is commonly used in the pharmaceutical industry to produce dry particles from liquids (FIGURE 2). Spray drying can be performed using water as the solvent, making it an advantageous approach. When spray drying with a Nano Spray Dryer, a piezoelectric actuator is driven at an ultrasonic frequency, generating vibrations that direct the injection of the liquid phase into an array of micron-sized holes. These holes form consistently-sized droplets that fall down a column under high pressures, quickly drying the droplets into dry particles. These particles are collected at the bottom of the column using an electrostatic precipitator. The method of spray drying is advantageous for albumin-based drug delivery because it is able to make compact particles with reproducible size, surface morphology, and release characteristics (Elzoghby et al., 2012) . 
B. Previous Work
Initial experiments were conducted to optimize curcumin solubility by binding it to various forms of albumin (CEW, BSA, and FAF BSA). Each type of albumin was examined at various concentrations (5%, 1%, and 0.1% w/v) in DI water. With each type of albumin, the increasing albumin concentrations resulted in increasing solubility of curcumin (FIGURE 3). After comparing the three types of albumin, statistical analysis showed that FAF BSA was able to solubilize the most curcumin. For spray drying studies, HSA was used given the therapeutic applications of albumin-curcumin particles in humans. Since FAF BSA was shown to bind more curcumin than BSA, FAF HSA was the type of albumin selected for particle fabrication.
FAF HSA-curcumin solutions were made with various albumin concentrations (0.1%, 0.5%, and 1% w/v) in DI water and then spray dried to form particles with a Buchi Nano B-90 spray dryer (head temperature of 120 o C, pressure of 45 hPa, drying gas flow rate of 150 L/min, peristaltic pump setting of 1, and mesh containing 4µm holes). To aid in particle formation, T20 (0.05% v/v) was added to the FAF HSA solutions prior to mixing with curcumin (Lee et al., 2011) .
With increased FAF HSA concentrations, there was an increase in the average particle size. By using dynamic light scattering, it was determined that the average particle size ranged from 369 ± 180 nm for 0.1% FAF HSA-curcumin particles to 481 ± 200 nm for 1% FAF HSA-curcumin particles. The 0.5% FAF HSA concentration was chosen as the concentration to produce spray dried particles that balanced smaller particle size with more curcumin binding. The T20 addition to 0.5% FAF HSA-curcumin produced particles with a more smooth and spherical morphology as shown in the scanning electron microscope images in FIGURE 4.
FIGURE 4 -Scanning electron microscope images of 0.5% FAF HSA-curcumin particles without and with 0.05% (v/v) T20 (Zeiss Evo, 20 kV, SE1 detector, sputter coated with gold/palladium for five minutes).
Without T20 With T20
Curcumin release from FAF HSA particles was examined over time and the release profile best fit a first-order (Ct/Cinf = 1 -e -kt , t = time) release. The protocol was adapted from Jithan et al., 2011 . The release of curcumin from 2 mg/ml of 0.5% FAF HSAcurcumin particles reached a saturation level in approximately 1 hour and followed the first-order model of Ct/Cinf = 1 -e -0.055t .
C. Albumin Crosslinking
Spray drying particles of albumin with bound curcumin allows for the production of particles with release characteristics that can be manipulated by using various production parameters or solution composition. The crosslinking of albumin was explored as a means for prolonging the release of bound curcumin because crosslinked albumin particles may need more time to solubilize and release curcumin. Additionally, the crosslinks on these albumin particles may extend the time needed for enzymatic breakdown once the particles enter a cell, prolonging the release of bound curcumin.
Three main crosslinking agents were considered -glutaraldehyde, BS 3 , and EDC.
These three crosslinking agents were initially chosen because of their solubility in water.
Glutaraldehyde is commonly used as a fixative because of its aggressive protein crosslinking ability (Migneault et al., 2004) . Though effective, glutaraldehyde has been classified as a skin, eye, and respiratory irritant (National Toxicology Program, 1999).
BS 3 is a homobifunctional crosslinking agent that reacts with primary amines such as those found on lysine residues or the N-terminus of a polypeptide (Huang et al., 2004) . It can perform its crosslinking procedure at physiologic conditions, but its cytotoxicity is still unknown. EDC is a zero-length crosslinker that crosslinks carboxylic acids to primary amines. Thus, there are 187 potential EDC crosslinking sites (lysine, arginine, glutamic acid, and aspartic acid residues, one polypeptide N-terminus, and one polypeptide C-terminus) per molecule of HSA, however there are two lysines located on the molecular surface (Sugio et al., 1999) . Additionally, no significant cytoxicity has been observed with EDC crosslinking (Park et al., 2002) . Sulfo-NHS is also watersoluble and is often used in conjunction with EDC to improve its crosslinking ability by creating stable amine-reactive intermediates (FIGURE 5) (Hermanson, 2013) . The advantages of the EDC/sulfo-NHS mechanism made it an ideal method to crosslink albumin for spray dried particle production. The crosslinking of albumin with EDC has not been previously explored for spray dried particles.
FIGURE 5 -Crosslinking mechanism for EDC with sulfo-NHS (Hayworth, 2014) D. Objective
The objective of this was work was to alter the release profile of curcumin from spray dried albumin particles by crosslinking albumin with EDC and sulfo-NHS. To achieve this goal, this work covalently crosslinked albumin using EDC and sulfo NHS, spray dried the crosslinked albumin to form particles, and characterized particle size, morphology, curcumin loading capacity, and release kinetics.
II. METHODS

A. Crosslinking Albumin with Glutaraldehyde
Initially, 0.5% (w/v) BSA in DI water was crosslinked using glutaraldehyde at 100:1 and 15:1 glutaraldehyde:BSA molar ratios (Fuguet et al., 2007) . Crosslinking was conducted on an orbital shaker for 24 hours at room temperature (20°C -25°C) in a 50 mL centrifuge tube. The solution was dialyzed in DI water for 24 hours to removed excess glutaraldehyde.
B. Crosslinking Albumin with EDC and Sulfo-NHS
A second crosslinking method was also explored. The crosslinking protocol was adapted from Bioconjugate Techniques (Hermanson, 2013) , and it crosslinked FAF HSA (SeraCare Life Sciences) using EDC (Acros Organics) and sulfo-NHS (Aldrich Chemistry). For this process, a final concentration of 0.01M EDC in DI water and 5mM sulfo-NHS in DI water were used to crosslink 0.5% (w/v) FAF HSA in DI water (7.5 x 10 -5 M). This solution was deemed a "1x" level of crosslinking based on the amount of EDC that was added. An EDC concentration of 0.1 M was used to crosslink at the 10x level (n = 1). The crosslinking process was conducted for 24 hours on an orbital shaker at room temperature in a 50 mL centrifuge tube. Based on the molar ratio of EDC to FAF HAS for the 1x conditions listed above, 134 crosslinks could be theoretically formed. 
E. Curcumin Binding
For the testing conditions with curcumin, 2.5 mg/ml curcumin (Sabinsa) and 0.05%
(v/v) T20 (Sigma) were added to the 1x FAF HSA in DI water after dialysis was complete. Due to curcumin's sensitivity to light, the solution was wrapped in aluminum foil once curcumin was added. The solution was placed on an orbital shaker for 24 hours at 4 °C. Curcumin was bound to FAF HSA in the presence of T20 using this same procedure.
After curcumin was allowed to bind to 1x FAF HSA-T20 and FAF HSA-T20, 
F. Quantification of Curcumin Bound to Albumin A standard curve was generated with curcumin initially dissolved in DMSO (Sigma Life Science) at a concentration of 5mM. UV-vis absorbance measurements were collected of a 0.125 mM curcumin solution that was created by diluting the 5mM curcumin in 0.5% FAF HSA in DI water with 0.05% T20. This solution was serially diluted in 0.5% FAF HSA in DI water with 0.05% T20 and vortexed to generate the standard curve. These measurements were blanked with a solution containing 50 µL of DMSO in 1.95 mL of 0.5% FAF HSA in DI water with 0.05% T20.
To determine the concentration of bound curcumin, supernatant absorbance was quantified using UV-visible spectroscopy (Thermo Scientific NanoDrop 2000c Spectrophotometer) at a wavelength of λ = 425 nm (the peak absorbance of curcumin) for solutions of FAF HSA-T20-curcumin (n = 3) and 1x FAF HSA-T20-curcumin (n = 3).
Results are reported as average ± SEM µM curcumin. Statistical significance was determined by conducting a t-test (Microsoft Excel) with unequal variances and α = 0.05 on the absorbance readings for the FAF HSA-T20-curcumin and 1x FAF HSA-T20curcumin solutions.
Measurements were also collected for negative control conditions of FAF HSA-T20 (n =1) and 1x FAF HSA-T20 (n = 1) in DI water. Three measurements were taken for each of these samples, and the reported values for curcumin binding are the average ± SEM µM curcumin of these three measurements. Molar ratios of bound curcumin to FAF HSA were calculated using Equation 2. 
G. Characterization of Particles
Particle size and morphology were characterized using scanning electron microscopy for FAF HSA-T20-curcumin (n = 3) and 1x FAF HSA-T20-curcumin (n = 3) particles. Particles were sprinkled onto carbon tape on pegs that were sputter coated with gold/palladium at 0.1 torr and 5mA for 4 minutes. Particles were visualized with a Zeiss Supra 35VP scanning electron microscope using a secondary electron detector with EHT = 2.0 kV. Three images were captured for each sample. Particle size was measured using ImageJ software developed by the National Institutes of Health (Rasband, 1997) . The scale bar on the original image was used to calibrate the dimensions of the image pixels.
The long axis of each particle whose full diameter was visible was measured and considered the particle diameter. Particles with smooth and spherical morphology were counted for each image, and these counts were normalized to the magnification of 54703 X (27.5 µm 2 image area). Results are reported as average ± SEM. Statistical significance was determined by conducting a t-test (Microsoft Excel) with unequal variances and α = 0.05 on the size and morphology measurements for FAF HSA-T20-curcumin and 1x FAF HSA-T20-curcumin particles. Images and measurements were also collected for negative control conditions of FAF HSA-T20 (n =1), 1x FAF HSA (n = 1) and 1x FAF HSA-T20
(n = 1) particles. Three measurements were taken for each of these samples, and the reported values are the average ± SEM of these three measurements.
H. Profiling Curcumin Release
Curcumin release from FAF HSA-T20-curcumin (n = 3) and 1x FAF HSA-T20curcumin (n = 3) spray dried particles over time was profiled via differential extraction and UV-visible spectroscopy (Jithan et al., 2011; O'Toole et al., 2012) . For differential extraction, the particles were added to 1% L-ascorbic acid (Sigma) in PBS (Fisher BioReagents) to make the aqueous layer. The solution was mixed via inversion of the tube, and then an equivalent volume of 0.1% BHT (Aldrich) in octanol (Sigma-Aldrich)
was gently added to serve as the organic layer. Particles were added at a concentration of 2 mg/mL based on the total volume of the aqueous and organic layers. Upon release from the particles, curcumin was pulled into the organic layer because of its hydrophobicity.
The absorbance of this organic layer was measured by using UV-visible spectroscopy (Thermo Scientific NanoDrop 2000c Spectrophotometer) at a wavelength of λ = 425 nm.
Spectral scans indicated that this was the peak absorbance for curcumin in octanol. The release study was considered complete once the absorbance readings from three consecutive time points confirmed a plateau for curcumin release. Curcumin concentration was calculated using a standard curve of curcumin in 0.1% BHT in octanol (2500 mM to 2.5 mM). Each solution was vortexed prior to collecting the absorbance readings. All readings were blanked with 0.1% BHT in octanol. As negative controls, release studies were also conducted with FAF HSA-T20 (n = 1) and 1x FAF HSA-T20 (n = 1) particles.
Raw curcumin release concentrations were converted to ratios of total released curcumin (Ct/Cinf). For each measurement, the curcumin concentrations of the final three time points were averaged and represented maximum curcumin release (Cinf). Curcumin concentrations for the earlier time points (Ct) were divided by this Cinf. Ct/Cinf became the dependent variable used to fit curcumin release profiles to the first-order mathematical model. First-order models were generated using Minitab 16 statistical analysis software.
SSE was used as an indicator of fit for the first-order model. Statistical significance was determined by conducting a t-test with unequal variances (Microsoft Excel, α = 0.05) on the sample k terms output for the first-order models of curcumin release from FAF HSA-T20-curcumin (n = 3) and 1x FAF HSA-T20-curcumin (n = 3) particles.
I. Additional Experiments
Additional studies were conducted to explore methods for optimizing the crosslinked FAF HSA spray dried particles. 1x FAF HSA (n = 1) in DI water was made with double the concentration of T20 (0.1%) to observe changes in particle morphology via scanning electron microscopy. Additionally, spray drying was attempted with a 2.5x FAF HSA-T20 solution (n = 1).
III. RESULTS AND DISCUSSION
A. Crosslinking Albumin with Glutaraldehyde BSA crosslinked with glutaraldehyde at 100:1 glutaraldehyde:BSA formed a gellike substance that could not be spray dried through the small diameter (4µm) holes in the spray drying mesh without causing clogging. The 15:1 glutaraldehyde:BSA appeared to have a lower viscosity that perhaps could have been spray dried. However, glutaraldehyde toxicity remained a concern for the therapeutic potential of spray dried particles made from this crosslinking technique (Atala and Lanza, 2002 ). An alternative method for crosslinking was simultaneously pursued to overcome some of the hurdles associated with the glutaraldehyde technique.
B. Crosslinking Albumin with EDC and Sulfo-NHS FAF HSA was crosslinked in DI water at various levels ranging from 1x to 10x based on the concentration of EDC used for the crosslinking. It was found that the 10x level of crosslinking produced a gel-like solution of crosslinked FAF HSA that was not able to be spray dried. The 1x crosslinked FAF HSA was able to be spray dried without clogging the spray mesh. Unless noted differently, the 1x condition was used in the subsequent studies to confirm FAF HSA crosslinking, characterize the particles, and profile curcumin release from the particles. Given that the final product being explored was FAF HSA in its spray dried form, melting points for spray dried FAF HSA particles were compared to the melting points of spray dried 1x FAF HSA particles using DSC. Reproducible and distinguishable endothermic peaks were identified (TABLE III) . The 1x FAF HSA particles had a melting point of 63.82 ± 2.34 o C, which was significantly higher (p = 0.0128) than the melting point of 53.60 ± 1.35 o C for the FAF HSA particles. With the additional bonds formed via crosslinking, an increase in the amount of energy needed to break these bonds and melt crosslinked FAF HSA was expected. Consequently, the higher melting point observed for 1x FAF HSA particles supported the Native PAGE conclusion that FAF HSA was crosslinked with the EDC/sulfo-NHS. Representative DSC curves are shown in The DSC curves for these measurements are depicted in FIGURE 7. FIGURE 7 -Representative DSC endothermic peak of 1x FAF HSA was shifted to the right from FAF HSA, which indicated a higher melting temperature for 1x FAF HSA. The concentration of curcumin bound to FAF HSA-T20 in DI water as measured prior to spray drying was 115.551 ± 6.918 µM. This was calculated to be a molar ratio of approximately 1.55:1 for curcumin:FAF HSA. The concentration of curcumin bound to 1x FAF HSA-T20 in DI water as measured prior to spray drying was 114.316 ± 9.970 µM. This was calculated to be a molar ratio of approximately 1.53:1 for curcumin:FAF HSA. As negative controls, FAF HSA-T20 and 1x FAF HSA-T20 exhibited negligible readings at 425 nm. Even though FAF HSA was crosslinked, these crosslinks did not significantly reduce curcumin binding (p = 0.9185) to the FAF HSA (FIGURE 8). Bound Curcumin Concentrations for FAF HSA-T20 and 1x FAF HSA-T20 Solutions FAF HSA-T20 FAF HSA-T20-Curc 1x FAF HSA-T20 1x FAF HSA-T20-Curc
Characterization of Particles
Morphology
Scanning electron microscopy images of the various spray dried particles are shown in TABLE IV. FAF HSA-T20 and FAF HSA-T20-curcumin particles showed spherical and smooth morphologies. Since the release of curcumin from spray dried albumin particles is affected by variations in particle shape and surface morphology, this spherical shape and uniform surface morphology was desirable. The 1x FAF HSA-T20 particles were not consistently spherical and smooth as observed with the FAF HSA-T20 particles produced under the same conditions. The 1x FAF HSA particles showed a wrinkled morphology that became smoother in the presence of T20 (this was also seen with FAF HSA, Lee et al., 2011) . The counts of particles with smooth and spherical morphology per 27.5 µm 2 area for FAF HSA-T20-curcumin were (55.5 ± 9.8) and 1x FAF HSA-T20curcumin (14.0 ± 2.1) (TABLE V) . Even though differences in morphology were observed between these conditions, the difference was not statistically significant (p = 0.0541). (Freitas, 1999 ) -an important upper size limit for the potential intravenous administration of these particles. The observed particle diameters fell well below this upper size limit. No statistical significance was observed between diameters for the FAF HSA-T20-curcumin particles and the 1x FAF HSA-T20-curcumin particles.
Therefore, crosslinking 0.5% FAF HSA with EDC and sulfo-NHS did not result in a significant change of particle diameter (p = 0.9889). The absorbance spectral scans shown in FIGURE 9 confirmed that curcumin's peak absorbance occurred at λ = 425 nm for these release studies. Curcumin release data for FAF HSA-T20 versus FAF HSA-T20-curcumin particles is shown in FIGURE 10 . The
Cinf for the FAF HSA-T20-curcumin particles was 137.796 ± 7.330 µM, and the Cinf for the 1x FAF HSA-T20-curcumin particles was 146.957 ± 5.414 µM. As negative controls, FAF HSA-T20 and 1x FAF HSA-T20 particles showed negligible absorbance at 425nm. determined from the first order fits to FAF HSA-T20-curcumin particles were 0.065 ± 0.003 and 1x FAF HSA-T20-curcumin particles was 0.049 ± 0.004. The release profile from 1x FAF HSA-T20-curcumin particles had a significantly (p = 0.0339) lower k than from FAF HSA-T20-curcumin particles, which implied a slower release.
FIGURE 11 shows the first-order models generated by Minitab software. Curcumin release from the FAF HSA-T20-curcumin particles had an SSE of 0.0006. Curcumin release from the 1x FAF HSA-T20-curcumin particles had an SSE of 0.0022. The low SSE values for both of these first-order models indicated that the first-order model was a good fit to the data and exploration of other release models was not needed.
Based on the first-order models that were generated, it took approximately 10.7 minutes for 50% of the maximum curcumin release to occur for the FAF HSA-T20curcumin particles as compared to approximately 14.1 minutes for the 1x FAF HSA-T20curcumin particles. It took approximately 46.1 minutes and 61.1 minutes for 95% of the maximum curcumin release to occur for the FAF HSA-T20-curcumin and 1x FAF HSA-T20-curcumin particles, respectively. This illustrates the slowed curcumin release from the crosslinked particles.
FIGURE 10 -Curcumin release data for FAF HSA-T20, FAF HSA-T20-curcumin, 1x
FAF HSA-T20, and 1x FAF HSA-T20-curcumin spray dried particles. Curcumin Release from Spray Dried FAF HSA-T20 and 1x FAF HSA-T20 Particles FAF HSA-T20 FAF HSA-T20-Curcumin 1x FAF HSA-T20 1x FAF HSA-T20-Curcumin By doubling the T20 that was added to 1x FAF HSA, the production of more spherical and smooth spray dried particles was observed (TABLE VI) . Spray drying of 2.5x FAF HSA-T20 was conducted without clogging of the spray mesh. Higher concentrations of T20 improved the morphology of 1x FAF HSA particles, and the feasibility of spray drying FAF HSA with increased levels of crosslinking was proven. Curcumin solubilization via binding to the 1x FAF HSA was not significantly altered by the formation of the crosslinks in albumin. Therefore the loading efficiencies of curcumin were the same for uncrosslinked and crosslinked albumin. The 1x FAF HSA was then spray dried to form particles that were 712.938 ± 65.292 nm in diameter.
Crosslinking albumin did not alter the diameter of the particles formed by spray drying, but the morphology of the particles was different when albumin was crosslinked.
The morphology of 1x FAF HSA particles was smoother with the addition of 0.05% T20, but 1x FAF HSA-T20 and 1x FAF HSA-T20-curcumin particles did not exhibit the same consistent spherical morphology as their FAF HSA-T20 and FAF HSA-T20curcumin counterparts. Counts for particles with smooth and spherical morphology were not statistically significant. Still, the difference in observed particle morphology (TABLE  IV) is of importance because it could contribute to altered curcumin release from 1x FAF HSA-T20-curcumin particles. No significant difference in particle diameter was observed for FAF HSA-T20-curcumin and 1x FAF HSA-T20-curcumin particles.
The release of curcumin from FAF HSA-T20-curcumin particles followed a firstorder release profile with the equation Ct/Cinf = 1-e -0.065t . The release of curcumin from 1x FAF HSA-T20-curcumin particles followed a first-order release profile with the equation Ct/Cinf = 1-e -0.049t . Statistical significance was observed between these two release profiles with the curcumin release from 1x FAF HSA-T20-curcumin particles being slowed.
Further extending curcumin release from FAF HSA particles should be explored by increasing the level of crosslinking. Crosslinking at a 2.5x level produced a solution that could be spray dried (while stirring constantly). The upper limit of crosslinking that is capable of being spray dried needs to be determined. Other techniques to form albumin nanoparticles such as electrospraying and others listed in the introduction chapter will need to be explored when the upper limit of crosslinking is reached.
The lower k value for the curcumin release from 1x FAF HSA-T20-curcumin particles indicated prolonged curcumin release from these particles as compared to the FAF HSA-T20-curcumin particles. In order to confirm that curcumin release is in fact delayed for EDC crosslinked FAF HSA particles, particle morphology must be improved to where smooth and spherical particles are consistently being produced via the spray drying process. Previously collected data showed that the addition of T20 aided in smooth albumin particle formation. Thus, one potential way to improve crosslinked particle morphology would be to increase the concentration of T20 used. Other parameters that should be investigated include changing the pump setting to "normal" speed and reducing the gas flow rate on the Buchi B-90 Nano spray dryer.
This work shows that crosslinking albumin with EDC and sulfo-NHS can produce spray dried particles with slowed curcumin release. The cytotoxicity of the crosslinked particles may be tested on cells in the future to show that they are non-toxic. The bioactivity of curcumin released from crosslinked particles can be observed by testing the viability of cancer cells treated with these particles. Curcumin delivery via spray dried albumin particles shows promise and should continue to be explored. 
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